| pubmed-article:19090877 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19090877 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19090877 | lifeskim:mentions | umls-concept:C0006684 | lld:lifeskim |
| pubmed-article:19090877 | lifeskim:mentions | umls-concept:C0011881 | lld:lifeskim |
| pubmed-article:19090877 | lifeskim:mentions | umls-concept:C0033687 | lld:lifeskim |
| pubmed-article:19090877 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19090877 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:19090877 | pubmed:dateCreated | 2008-12-18 | lld:pubmed |
| pubmed-article:19090877 | pubmed:abstractText | Diabetic nephropathy management should include the use of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker with additional antihypertensive medications to reduce proteinuria and cardiovascular events. Some studies suggest that adding a nondihydropyridine rather than a dihydropyridine calcium channel blocker (CCB) may more effectively lower proteinuria. We hypothesized that a trandolapril/verapamil SR (T/V) fixed-dose combination (FDC) was superior to a benazepril/amlodipine (B/A) FDC for reducing albuminuria in 304 hypertensive diabetic nephropathy patients when treated for 36 weeks. No statistically significant differences were observed between groups in the primary end point; adjusted percentage change in urinary albumin/creatinine ratio (UACR), which increased (mean T/V, 29.29%; mean B/A, 8.49%; difference, 20.80%; P=.34); or in change in absolute UACR, which decreased (mean [g/g] T/V, -0.11; mean [g/g] B/A, -0.08; difference -0.03; P=.78). There were significant reductions in log UACR (mean change in T/V, -0.28; P<.01; mean change in B/A, -0.31; P<.001) and diastolic blood pressure in both groups and in systolic blood pressure in the B/A group. T/V was not superior to B/A for reducing UACR. Both ACEI/CCB FDCs may reduce albuminuria; in the case of T/V, this appears to be independent of systolic blood pressure reduction in patients who had previously been treated and had baseline blood pressure levels of 142/77 mm Hg. | lld:pubmed |
| pubmed-article:19090877 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19090877 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19090877 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19090877 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:19090877 | pubmed:issn | 1524-6175 | lld:pubmed |
| pubmed-article:19090877 | pubmed:author | pubmed-author:TotoRobert... | lld:pubmed |
| pubmed-article:19090877 | pubmed:author | pubmed-author:FakouhiKaffaK | lld:pubmed |
| pubmed-article:19090877 | pubmed:author | pubmed-author:BacherPeterP | lld:pubmed |
| pubmed-article:19090877 | pubmed:author | pubmed-author:TianMinM | lld:pubmed |
| pubmed-article:19090877 | pubmed:author | pubmed-author:ChampionAnnet... | lld:pubmed |
| pubmed-article:19090877 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19090877 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:19090877 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19090877 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19090877 | pubmed:pagination | 761-9 | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:meshHeading | pubmed-meshheading:19090877... | lld:pubmed |
| pubmed-article:19090877 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:19090877 | pubmed:articleTitle | Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy. | lld:pubmed |
| pubmed-article:19090877 | pubmed:affiliation | Department of Internal Medicine, Division of Nephrology, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8856, USA. robert.toto@utsouthwestern.edu | lld:pubmed |
| pubmed-article:19090877 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19090877 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19090877 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19090877 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19090877 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:19090877 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
